PHONEBRASIL INTERNATIONAL (OTC: PHBR)
Detailed Quote: http://www.otcpicks.com/quotes/PHBR.php
Company Profile: http://www.otcpicks.com/phonebrasil-int-l./phonebrasil-international.htm
PhoneBrasil International, Inc. is an American-based company specializing in Hybrid VOIP, cellular, Broadband and WIFI Technology in the Latin American market as well as servicing the International Telecommunication Markets. PhoneBrasil was recently awarded with a governmental contract for telecommunications service within the territory of the Country of Columbia.
PHBR News:
October 4 - PhoneBrasil Finalizes Agreement to Acquire Office Building in Madrid, Spain
PhoneBrasil International, Inc. (Pink Sheets:PHBR) announced today that it has reached an agreement to acquire a 1,200 m2 (about 13,000 sq ft) office complex in Madrid, Spain. This agreement is for the entire 3rd floor of the 25 story office building along with 7 parking markets and one retail store on the first floor. The retail office will be for PHBR and its Hybrid VOIP, cellular, Broadband and WIFI Technology. The current valuation of this property is 8.120.000 Euros = $11.368.000 USD.
The Company plans to occupy the 3th floor of the office complex establishing it as its headquarters for Spain. The building also has as a tenant Telindus-Belgian Com. The office complex is next to one of the greater installations of Telefonica SA (NYSE:TEF) which is the headquarters of their Department of Engineering and Systems.
"We now have physical facilities in Miami, Florida; Brazil and Madrid, Spain," stated Anderson Diaz, President of PhoneBrasil. "We now have the facilities to fully implement our immediate business plan, which shows us to be a serious international telecommunications company."
BLACK DRAGON RESOURCES (OTC: BDGR | charts | news | PowerRating) "Up 17.86% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BDGR.php
Black Dragon Resource Companies, Inc. is an oil and gas exploration and production company currently focused on the acquisition of mature, producing and existing domestic oil and gas fields. This focus has eliminated exploration risk, reduced costs of completion, and provided rapid generation of income in a niche market where larger independent and major oil companies are not positioned to compete. Black Dragon intends to recomplete additional shallow producing wells and to expand its focus to include drilling of new wells some to deeper levels and to purchase additional leases.
BDGR News:
October 5 - Black Dragon Announces a Joint Venture Starting the Week of October 8, 2007
Black Dragon Resource Companies, Inc. (PINKSHEETS: BDGR | charts | news | PowerRating) ("the Company," "the Dragon") announced today that Dragon and a Working Interest Holder are going to reevaluate a gas and oil well drilled in the early 90s but never fraced. The reason behind the re-evaluation is a well drilled six months ago, close to Dragon's No. 67 and fraced, was a success. The plan is if this frace on Well No. 67 is successful, there are 9 other gas wells never fraced, just shot, that can be reevaluated.
The goal is the well will produce 18 more barrels of oil a day and 150,000 mcf of gas.
18 barrels x 30 days = 540 barrels x $76.00 = $41,040.00/2 = $20,520.00 x 73% net revenue = $14,979.60 per month.
150,000 mcf x 30 days = 4,500,000 x 6.55 = $29,475.00/2 = 14,737.50 x 73% net revenue = $10,758.37 x 91% net gas = $9,790.11 per month.
$24,769.71 for 50% of one well x 10 wells could equal $247,697.10 or more additional revenue per month. Management stated if the first well comes in, the rest could be finished up in November.
TRUSTCASH HOLDINGS (OTCBB: TCHH | charts | news | PowerRating) "Up 20% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/TCHH.php
Through its Trustcash brand and website www.trustcash.com, the Company is a pioneer of anonymous payment systems for the internet. It developed a business based on the sale of a stored value card (both virtual and physical) that can be used by consumers to make secure and anonymous purchases on the internet without disclosing their credit card or personal information. Trustcash provides to its customers the "Trustcash" payment card, which is sold in denominations ranging from $10 to $200 either online, through any of over 500 websites, or at over 50,000 retail locations in the United States via MoneyGram. Trustcash's non-reloadable, virtual Trustcash card is the only "stored value card" that can be purchased where no personal data is stored or available, providing a unique level of both security and privacy to the purchaser.
TCHH News:
October 7 - Trustcash Provides Additional Information on Proposed Acquisition/Merger
Trustcash Holdings, Inc. (OTCBB:TCHH) confirms that the term sheet referred to in the October 5, 2007 news release from the Company is a binding agreement (the "Agreement"). The Agreement with Paivis, Corp. ("Paivis") outlines the terms of an acquisition/merger wherein Trustcash will acquire all of the issued and outstanding Common and Preferred shares of Paivis and its subsidiaries; on a share for share basis. The closing of the merger is subject to amongst other things the completion of legal and financial due diligence. This Agreement will be filed, in the form required, with the Securities and Exchange Commission within the required timeframe.
AVANIR PHARMACEUTICALS (NASD: AVNR | charts | news | PowerRating) "Up 19.90% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AVNR.php
AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system (CNS), inflammation and infectious diseases. AVANIR's lead product candidate Zenvia is being developed for the treatment of pseudobulbar affect (PBA) and is the subject of an approvable letter from the FDA for that indication. Additionally, in April 2007 AVANIR announced meeting all primary endpoints in a Phase III clinical trial with Zenvia in patients with diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed a compound to Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease. AVANIR's infectious disease drug candidate, AVP-21D9, is a human monoclonal antibody in pre-clinical development for the treatment of anthrax with funding provided to date from an NIH/NIAID grant. The Company's first commercialized product, Abreva , is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
AVNR News:
October 8 - AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced that it has reached a definitive agreement with the U.S. Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of a single confirmatory Phase III clinical trial of Zenvia (dextromethorphan/quinidine [DM/Q]) for the treatment of patients with pseudobulbar affect (PBA). AVANIR trial 07-AVR-123 "A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients with Amyotrophic Lateral Sclerosis and Multiple Sclerosis" (otherwise known as the "STAR trial") is expected to begin enrolling patients by the end of 2007.
"We now have a clear path toward gaining regulatory approval for Zenvia in this important indication and continue on track to begin patient enrollment in this trial before 2007 calendar year end," said Randall Kaye, MD, Chief Medical Officer of AVANIR. "We have developed an alternative formulation of Zenvia with a lower dose of the quinidine component than the formulation used in earlier PBA studies. Based on our extensive PK/PD modeling, we expect that the new formulation of Zenvia will demonstrate acceptable safety and tolerability, while continuing to provide significant efficacy."
"The STAR trial represents an important milestone for greater than one million Americans thought to suffer from the debilitating episodes of PBA," said Jeffrey Cummings, MD, Executive Vice Chair of the Department of Neurology at the David Geffen School of Medicine at UCLA and lead investigator of the STAR trial. "With no currently approved treatment options available, the STAR trial is an essential step toward making Zenvia available to patients with PBA."
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has received seven thousand free trading shares from a third party (Media Capital) for PHBR advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
